Sonova Holding AG

SOON.SW

Medical - Devices · Healthcare

Also trades as: SONVY · 0QPY.L

Price

CHF 239.80

+0.80 (+0.33%)

Market Cap

CHF 14.25B

Exchange

SIX Swiss Exchange

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Data as of Aug 12, 2026 · filings through Mar 31, 2026

Share count falling — buybacks

−3.5% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 62.7M (2022) → 60.5M (2026)

Sonova is a Swiss company that makes hearing aids and related products for people with hearing loss. Its main brands include Phonak, Unitron, and Hansaton, and it also owns AudioNova, a chain of hearing care clinics. Sonova sells to audiologists, hearing care professionals, and directly to consumers, making it one of the largest hearing health companies in the world.

The company earns money by selling hearing aid devices, accessories, and cochlear implants, as well as through its retail hearing clinic network. Sonova operates globally, with strong presence in Europe, North America, and Asia, and generates roughly $2 billion in annual revenue. Its competitive edge comes from heavy investment in research and development, strong brand recognition, and proprietary wireless audio technology. The key growth driver is an aging global population, which is expected to increase demand for hearing solutions over the coming decades, though currency fluctuations and pricing pressure from lower-cost competitors remain ongoing risks.

Winston Score History

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

78.7%

Premium pricing power — 78.7% gross margin

Operating Margin

21.6%

Excellent — 21.6% operating margin

ROCE

9.5%

Below par — 9.5% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-6.7%

Shrinking sales (-6.7% YoY)

EPS YoY

-20.3%

Earnings shrinking (-20.3% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

127%

Turns 127% of profit into real cash

FCF Margin

16.7%

Converts sales into free cash efficiently (16.7%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.56

Conservative — low debt load (0.56)

Interest Cover

7.72x

Adequate interest coverage (7.7x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

33.2x

Pricey — P/E 33.2

P/E above the market average. People are paying up for expected growth.

P/E vs Forward

+15.3

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (33.2 → 17.8)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield

1.99%

Small dividend — 1.99% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend Growth

+37.6%

Dividend growing fast (37.6% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial